Oct. 25 at 8:32 AM
$ITRM Pfizer is currently thinking solely about Viking Therapeutics. They have a weight-loss drug that could generate revenues 1 million times higher than these. In fact, there's talk of a potential BO of 10 billion. If Pfizer hasn't purchased, it's because they're not interested in the tips. Our product, under full capacity, could generate revenues for 80 million years, which, when multiplied by the exclusivity period, gives it a potentially uninteresting value. I think another pharma will come forward, smaller, more modest, and more in line with our product. Pfizer sells non-therapeutic products, as per its credo, with high profitability. The problem of delays and long lead times is that our potential buyer is not like Pfizer, which has 30 billion in liquidity. This company is more modest and has limited liquidity, so it needs to be certain before spending.
